Padcev and Keytruda Combination Therapy: A Validated Treatment for Advanced Bladder Cancer
Padcev (enfortumab vedotin-ejfv) and Keytruda (pembrolizumab) have received regulatory approval as a first-line treatment for patients with locally advanced or metastatic urothelial carcinoma, a type of bladder cancer. This combination represents a significant advancement in oncology, offering a new option for individuals who may not be eligible for cisplatin-based chemotherapy. The U.S. Food and Drug Administration (FDA) granted accelerated approval to this regimen in December 2021, based on the results of the EV-302 clinical trial. Subsequent full approval followed in March 2023 after the trial demonstrated a statistically significant improvement in overall survival compared to chemotherapy alone.
How Padcev and Keytruda Work Together
Padcev is an antibody-drug conjugate (ADC) that targets Nectin-4, a protein overexpressed on the surface of many urothelial cancer cells. The drug consists of a monoclonal antibody linked to the cytotoxic agent monomethyl auristatin E (MMAE). When Padcev binds to Nectin-4, it is internalized by the cancer cell, releasing MMAE, which disrupts microtubule formation and leads to cell death. Keytruda is a programmed death-1 (PD-1) inhibitor that blocks the PD-1 receptor on T cells, preventing cancer cells from evading immune detection. By inhibiting PD-1, Keytruda enhances the body’s immune response against tumor cells. The combination of these two mechanisms—direct cytotoxic action and immune system activation—provides a synergistic effect that improves treatment outcomes.
Clinical Evidence Supporting the Combination
The pivotal EV-302 trial (NCT04223856) compared Padcev plus Keytruda to gemcitabine plus cisplatin or carboplatin chemotherapy in 886 patients with previously untreated advanced urothelial carcinoma. The study’s primary endpoint was overall survival (OS). At the time of the interim analysis, the combination therapy showed a 31% reduction in the risk of death (hazard ratio [HR] 0.69; 95% CI, 0.55–0.86; p=0.001) compared to chemotherapy. Median overall survival was not yet reached in the combination arm at the interim analysis, while it was 16.1 months in the chemotherapy arm. The final analysis, presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, confirmed a median OS of 23.0 months for the Padcev-Keytruda group versus 16.1 months for chemotherapy (HR 0.67; 95% CI, 0.54–0.83; p=0.0003). Progression-free survival (PFS) was similarly significantly improved, with a median PFS of 9.2 months versus 6.3 months for chemotherapy (HR 0.56; 95% CI, 0.45–0.70; p<0.0001). The objective response rate (ORR) was 68% in the combination group compared to 44% in the chemotherapy group. These results led to the FDA's full approval of the regimen in March 2023.
Eligibility and Administration
Padcev plus Keytruda is indicated for adults with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-containing chemotherapy. Eligibility criteria include an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and adequate organ function. Patients with severe hepatic impairment (Child-Pugh C) or those who have
Padcev and Keytruda Combination Therapy: A Validated Treatment for Advanced Bladder Cancer
Padcev (enfortumab vedotin-ejfv) and Keytruda (pembrolizumab) have received regulatory approval as a first-line treatment for patients with locally advanced or metastatic urothelial carcinoma, a type of bladder cancer. This combination represents a significant advancement in oncology, offering a new option for individuals who may not be eligible for cisplatin-based chemotherapy. The U.S. Food and Drug Administration (FDA) granted accelerated approval to this regimen in December 2021, based on the results of the EV-302 clinical trial. Subsequent full approval followed in March 2023 after the trial demonstrated a statistically significant improvement in overall survival compared to chemotherapy alone.
How Padcev and Keytruda Work Together
Padcev is an antibody-drug conjugate (ADC) that targets Nectin-4, a protein overexpressed on the surface of many urothelial cancer cells. The drug consists of a monoclonal antibody linked to the cytotoxic agent monomethyl auristatin E (MMAE). When Padcev binds to Nectin-4, it is internalized by the cancer cell, releasing MMAE, which disrupts microtubule formation and leads to cell death. Keytruda is a programmed death-1 (PD-1) inhibitor that blocks the PD-1 receptor on T cells, preventing cancer cells from evading immune detection. By inhibiting PD-1, Keytruda enhances the body’s immune response against tumor cells. The combination of these two mechanisms—direct cytotoxic action and immune system activation—provides a synergistic effect that improves treatment outcomes.
Clinical Evidence Supporting the Combination
The pivotal EV-302 trial (NCT04223856) compared Padcev plus Keytruda to gemcitabine plus cisplatin or carboplatin chemotherapy in 886 patients with previously untreated advanced urothelial carcinoma. The study’s primary endpoint was overall survival (OS). At the time of the interim analysis, the combination therapy showed a 31% reduction in the risk of death (hazard ratio [HR] 0.69; 95% CI, 0.55–0.86; p=0.001) compared to chemotherapy. Median overall survival was not yet reached in the combination arm at the interim analysis, while it was 16.1 months in the chemotherapy arm. The final analysis, presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, confirmed a median OS of 23.0 months for the Padcev-Keytruda group versus 16.1 months for chemotherapy (HR 0.67; 95% CI, 0.54–0.83; p=0.0003). Progression-free survival (PFS) was also significantly improved, with a median PFS of 9.2 months versus 6.3 months for chemotherapy (HR 0.56; 95% CI, 0.45–0.70; p<0.0001). The objective response rate (ORR) was 68% in the combination group compared to 44% in the chemotherapy group. These results led to the FDA's full approval of the regimen in March 2023.
Eligibility and Administration
Padcev plus Keytruda is indicated for adults with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-containing chemotherapy. Eligibility criteria include an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and adequate organ function. Patients with severe hepatic impairment (Child-Pugh C) or those who have
Padcev and Keytruda Combination Therapy: A Validated Treatment for Advanced Bladder Cancer
Padcev (enfortumab vedotin-ejfv) and Keytruda (pembrolizumab) have received regulatory approval as a first-line treatment for patients with locally advanced or metastatic urothelial carcinoma, a type of bladder cancer. This combination represents a significant advancement in oncology, offering a new option for individuals who may not be eligible for cisplatin-based chemotherapy. The U.S. Food and Drug Administration (FDA) granted accelerated approval to this regimen in December 2021, based on the results of the EV-302 clinical trial. Subsequent full approval followed in March 2023 after the trial demonstrated a statistically significant improvement in overall survival compared to chemotherapy alone.
How Padcev and Keytruda Work Together
Padcev is an antibody-drug conjugate (ADC) that targets Nectin-4, a protein overexpressed on the surface of many urothelial cancer cells. The drug consists of a monoclonal antibody linked to the cytotoxic agent monomethyl auristatin E (MMAE). When Padcev binds to Nectin-4, it is internalized by the cancer cell, releasing MMAE, which disrupts microtubule formation and leads to cell death. Keytruda is a programmed death-1 (PD-1) inhibitor that blocks the PD-1 receptor on T cells, preventing cancer cells from evading immune detection. By inhibiting PD-1, Keytruda enhances the body’s immune response against tumor cells. The combination of these two mechanisms—direct cytotoxic action and immune system activation—provides a synergistic effect that improves treatment outcomes.
Clinical Evidence Supporting the Combination
The pivotal EV-302 trial (NCT04223856) compared Padcev plus Keytruda to gemcitabine plus cisplatin or carboplatin chemotherapy in 886 patients with previously untreated advanced urothelial carcinoma. The study’s primary endpoint was overall survival (OS). At the time of the interim analysis, the combination therapy showed a 31% reduction in the risk of death (hazard ratio [HR] 0.69; 95% CI, 0.55–0.86; p=0.001) compared to chemotherapy. Median overall survival was not yet reached in the combination arm at the interim analysis, while it was 16.1 months in the chemotherapy arm. The final analysis, presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, confirmed a median OS of 23.0 months for the Padcev-Keytruda group versus 16.1 months for chemotherapy (HR 0.67; 95% CI, 0.54–0.83; p=0.0003). Progression-free survival (PFS) was also significantly improved, with a median PFS of 9.2 months versus 6.3 months for chemotherapy (HR 0.56; 95% CI, 0.45–0.70; p<0.0001). The objective response rate (ORR) was 68% in the combination group compared to 44% in the chemotherapy group. These results led to the FDA's full approval of the regimen in March 2023.
Eligibility and Administration
Padcev plus Keytruda is indicated for adults with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-containing chemotherapy. Eligibility criteria include an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and adequate organ function. Patients with severe hepatic impairment (Child-Pugh C) or those who have
Padcev and Keytruda Combination Therapy: A Validated Treatment for Advanced Bladder Cancer
Padcev (enfortumab vedotin-ejfv) and Keytruda (pembrolizumab) have received regulatory approval as a first-line treatment for patients with locally advanced or metastatic urothelial carcinoma, a type of bladder cancer. This combination represents a significant advancement in oncology, offering a new option for individuals who may not be eligible for cisplatin-based chemotherapy. The U.S. Food and Drug Administration (FDA) granted accelerated approval to this regimen in December 2021, based on the results of the EV-302 clinical trial. Subsequent full approval followed in March 2023 after the trial demonstrated a statistically significant improvement in overall survival compared to chemotherapy alone.
How Padcev and Keytruda Work Together
Padcev is an antibody-drug conjugate (ADC) that targets Nectin-4, a protein overexpressed on the surface of many urothelial cancer cells. The drug consists of a monoclonal antibody linked to the cytotoxic agent monomethyl auristatin E (MMAE). When Padcev binds to Nectin-4, it is internalized by the cancer cell, releasing MMAE, which disrupts microtubule formation and leads to cell death. Keytruda is a programmed death-1 (PD-1) inhibitor that blocks the PD-1 receptor on T cells, preventing cancer cells from evading immune detection. By inhibiting PD-1, Keytruda enhances the body’s immune response against tumor cells. The combination of these two mechanisms—direct cytotoxic action and immune system activation—provides a synergistic effect that improves treatment outcomes.
Clinical Evidence Supporting the Combination
The pivotal EV-302 trial (NCT04223856) compared Padcev plus Keytruda to gemcitabine plus cisplatin or carboplatin chemotherapy in 886 patients with previously untreated advanced urothelial carcinoma. The study’s primary endpoint was overall survival (OS). At the time of the interim analysis, the combination therapy showed a 31% reduction in the risk of death (hazard ratio [HR] 0.69; 95% CI, 0.55–0.86; p=0.001) compared to chemotherapy. Median overall survival was not yet reached in the combination arm at the interim analysis, while it was 16.1 months in the chemotherapy arm. The final analysis, presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, confirmed a median OS of 23.0 months for the Padcev-Keytruda group versus 16.1 months for chemotherapy (HR 0.67; 95% CI, 0.54–0.83; p=0.0003). Progression-free survival (PFS) was also significantly improved, with a median PFS of 9.2 months versus 6.3 months for chemotherapy (HR 0.56; 95% CI, 0.45–0.70; p<0.0001). The objective response rate (ORR) was 68% in the combination group compared to 44% in the chemotherapy group. These results led to the FDA's full approval of the regimen in March 2023.
Eligibility and Administration
Padcev plus Keytruda is indicated for adults with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-containing chemotherapy. Eligibility criteria include an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and adequate organ function. Patients with severe hepatic impairment (Child-Pugh C) or those who have
Padcev and Keytruda Combination Therapy: A Validated Treatment for Advanced Bladder Cancer
Padcev (enfortumab vedotin-ejfv) and Keytruda (pembrolizumab) have received regulatory approval as a first-line treatment for patients with locally advanced or metastatic urothelial carcinoma, a type of bladder cancer. This combination represents a significant advancement in oncology, offering a new option for individuals who may not be eligible for cisplatin-based chemotherapy. The U.S. Food and Drug Administration (FDA) granted accelerated approval to this regimen in December 2021, based on the results of the EV-302 clinical trial. Subsequent full approval followed in March 2023 after the trial demonstrated a statistically significant improvement in overall survival compared to chemotherapy alone.
How Padcev and Keytruda Work Together
Padcev is an antibody-drug conjugate (ADC) that targets Nectin-4, a protein overexpressed on the surface of many urothelial cancer cells. The drug consists of a monoclonal antibody linked to the cytotoxic agent monomethyl auristatin E (MMAE). When Padcev binds to Nectin-4, it is internalized by the cancer cell, releasing MMAE, which disrupts microtubule formation and leads to cell death. Keytruda is a programmed death-1 (PD-1) inhibitor that blocks the PD-1 receptor on T cells, preventing cancer cells from evading immune detection. By inhibiting PD-1, Keytruda enhances the body’s immune response against tumor cells. The combination of these two mechanisms—direct cytotoxic action and immune system activation—provides a synergistic effect that improves treatment outcomes.
Clinical Evidence Supporting the Combination
The pivotal EV-302 trial (NCT04223856) compared Padcev plus Keytruda to gemcitabine plus cisplatin or carboplatin chemotherapy in 886 patients with previously untreated advanced urothelial carcinoma. The study’s primary endpoint was overall survival (OS). At the time of the interim analysis, the combination therapy showed a 31% reduction in the risk of death (hazard ratio [HR] 0.69; 95% CI, 0.55–0.86; p=0.001) compared to chemotherapy. Median overall survival was not yet reached in the combination arm at the interim analysis, while it was 16.1 months in the chemotherapy arm. The final analysis, presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, confirmed a median OS of 23.0 months for the Padcev-Keytruda group versus 16.1 months for chemotherapy (HR 0.67; 95% CI, 0.54–0.83; p=0.0003). Progression-free survival (PFS) was also significantly improved, with a median PFS of 9.2 months versus 6.3 months for chemotherapy (HR 0.56; 95% CI, 0.45–0.70; p<0.0001). The objective response rate (ORR) was 68% in the combination group compared to 44% in the chemotherapy group. These results led to the FDA's full approval of the regimen in March 2023.
Eligibility and Administration
Padcev plus Keytruda is indicated for adults with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-containing chemotherapy. Eligibility criteria include an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and adequate organ function. Patients with severe hepatic impairment (Child-Pugh C) or those who have
Padcev and Keytruda Combination Therapy: A Validated Treatment for Advanced Bladder Cancer
Padcev (enfortumab vedotin-ejfv) and Keytruda (pembrolizumab) have received regulatory approval as a first-line treatment for patients with locally advanced or metastatic urothelial carcinoma, a type of bladder cancer. This combination represents a significant advancement in oncology, offering a new option for individuals who may not be eligible for cisplatin-based chemotherapy. The U.S. Food and Drug Administration (FDA) granted accelerated approval to this regimen in December 2021, based on the results of the EV-302 clinical trial. Subsequent full approval followed in March 2023 after the trial demonstrated a statistically significant improvement in overall survival compared to chemotherapy alone.
How Padcev and Keytruda Work Together
Padcev is an antibody-drug conjugate (ADC) that targets Nectin-4, a protein overexpressed on the surface of many urothelial cancer cells. The drug consists of a monoclonal antibody linked to the cytotoxic agent monomethyl auristatin E (MMAE). When Padcev binds to Nectin-4, it is internalized by the cancer cell, releasing MMAE, which disrupts microtubule formation and leads to cell death. Keytruda is a programmed death-1 (PD-1) inhibitor that blocks the PD-1 receptor on T cells, preventing cancer cells from evading immune detection. By inhibiting PD-1, Keytruda enhances the body’s immune response against tumor cells. The combination of these two mechanisms—direct cytotoxic action and immune system activation—provides a synergistic effect that improves treatment outcomes.
Clinical Evidence Supporting the Combination
The pivotal EV-302 trial (NCT04223856) compared Padcev plus Keytruda to gemcitabine plus cisplatin or carboplatin chemotherapy in 886 patients with previously untreated advanced urothelial carcinoma. The study’s primary endpoint was overall survival (OS). At the time of the interim analysis, the combination therapy showed a 31% reduction in the risk of death (hazard ratio [HR] 0.69; 95% CI, 0.55–0.86; p=0.001) compared to chemotherapy. Median overall survival was not yet reached in the combination arm at the interim analysis, while it was 16.1 months in the chemotherapy arm. The final analysis, presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, confirmed a median OS of 23.0 months for the Padcev-Keytruda group versus 16.1 months for chemotherapy (HR 0.67; 95% CI, 0.54–0.83; p=0.0003). Progression-free survival (PFS) was also significantly improved, with a median PFS of 9.2 months versus 6.3 months for chemotherapy (HR 0.56; 95% CI, 0.45–0.70; p<0.0001). The objective response rate (ORR) was 68% in the combination group compared to 44% in the chemotherapy group. These results led to the FDA's full approval of the regimen in March 2023.
Eligibility and Administration
Padcev plus Keytruda is indicated for adults with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-containing chemotherapy. Eligibility criteria include an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and adequate organ function. Patients with severe hepatic impairment (Child-Pugh C) or those who have